ImaCor Inc., the developer of the world’s first and only hemodynamic transesophageal echocardiography (hTEE™) technology, announced today four major academic hTEE presentations. Renowned physicians are publicly recognizing hTEE as an essential tool for managing complex ICU patients. This week Nick Fletcher MBBS presents hTEE during the Heart Failure: State of the Art and Future Perspectives 5-day European Association of Cardio-Thoracic Surgery (EACTS) advanced module in Windsor, UK; Serban Bubenek MD, PhD describes hTEE as the Advanced Hemodynamic Management solution at the Autumn Meeting of the European Society of Anesthesiology (ESA) in Timisoara, Romania; and Margarita Camacho MD and Claudia Gidea MD share hTEE case findings at the Tufts 6th Annual New England Heart Failure and Transplantation Network Conference in Waltham, Massachusetts.
This follows an October 8, 2013 session on hTEE Advanced Hemodynamic Management that was part of the scientific program at the 27th Annual Meeting of EACTS in Vienna, Austria. Speakers included A. Pieter Kappetein MD, PhD, Matthias Loebe MD, PhD, and Simon Maltais MD, PhD. During the 90-minute session, three videos of live hTEE case demonstrations were also presented from Vanderbilt University Medical Center (Nashville), Barnes-Jewish Hospital (St. Louis), and Thomas Jefferson University Medical Center (Philadelphia).
hTEE is enabled through a miniature, disposable probe that can be placed in a patient for up to 72 hours to directly observe cardiac filling and function over time. It is easy-to-use and purpose-built for the ICU staff. With the growing population of older, sicker patients with multiple comorbidities, physicians recognize the benefits of hTEE’s continuous hemodynamic management to guide therapy. ImaCor’s highly-differentiated hTEE Advanced Hemodynamic Management Program delivers superior outcomes and reduces cost of care.
ImaCor Inc. is a privately held company headquartered in Garden City, NY. The company designs, manufactures, and distributes advanced solutions for hemodynamic assessment in the critical care environment for the purpose of improving patient outcomes and optimizing utilization of healthcare resources. ImaCor manufactures the ClariTEE® probe, the only miniaturized, indwelling TEE probe suitable for long-term clinical settings. hTEE™, Zura™, Zura EVO™, Adaptaflex™, and ClariTEE® are trademarks of ImaCor, Inc. For more information, please visit our website at www.imacorinc.com. Follow us on Facebook, Twitter, and YouTube.